Income statement
USD
Annual
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 35M | 3M | 0 | 0 | 0 |
| Gross Profit | 29M | 2M | 0 | 0 | -2M |
| Operating Income | -87M | -36M | -108M | -88M | -75M |
| EBITDA | -86M | -28M | -95M | -89M | -73M |
| Net Income | -79M | -37M | -101M | -94M | -89M |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$4.22
+4.20% today
1Y Change
+65.29%
Window
Jun 23, 2025 → Jun 12, 2026
Coverage: 245 bars · Jun 23, 2025 → Jun 12, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
X4 Pharmaceuticals, Inc. (XFOR) is a Healthcare stock with a market cap of $50.00M and listed on NASDAQ. The stock last traded around $4.22 and up 65.3% across the available one-year price window (Jun 23, 2025 → Jun 12, 2026). Baseline metrics include revenue growth of +1273.2%, EPS growth of +66.5%, a dividend yield of 0.0%. What stands out right now is revenue +1273.2%, EPS +66.5%, free cash flow +35.9% with operating margin -247.4% and ROIC -32.7%. Valuation is more restrained than many high-expectation growth names at price/sales 1.4. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines XFOR price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
XFOR
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
XFOR Max Drawdown
-41.32%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for XFOR and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$0.0
FY Net Income
-$88.7M
+5.5% YoY
Free Cash Flow
-$71.5M
+7.4% YoY
Revenue Growth
+1273.2%
EPS Growth
+66.5%
Gross Margin
82.2%
Net Margin
-225.6%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 35M | 3M | 0 | 0 | 0 |
| Gross Profit | 29M | 2M | 0 | 0 | -2M |
| Operating Income | -87M | -36M | -108M | -88M | -75M |
| EBITDA | -86M | -28M | -95M | -89M | -73M |
| Net Income | -79M | -37M | -101M | -94M | -89M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 217M | 56M | 99M | 122M | 82M |
| Total Assets | 290M | 146M | 147M | 156M | 117M |
| Total Liabilities | 104M | 124M | 96M | 82M | 53M |
| Shareholder Equity | 186M | 22M | 51M | 74M | 64M |
| Total Debt | 77M | 78M | 58M | 38M | 40M |
| Net Debt | -140M | 22M | -41M | -83M | -42M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
71M
+8.0% YoY
Capital Expenditures
615K
-497.1% YoY
Free Cash Flow
72M
+7.4% YoY
Key ratios
Gross Margin
82.2%
Operating Margin
-247.4%
Net Margin
-225.6%
ROE
-115.3%
Debt / Equity
0.41x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.